Overlap syndromes: An emerging diagnostic and therapeutic challenge

Saudi Journal of Gastroenterology

Volumn 20, Issue 6, 2014, Pages 342-349

  Dhiman, Pooja ^a   Malhotra, Sharad ^b  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b Batra Hospital India   (India)

Author keywords

Autoantibodies; autoimmune; biliary; overlap

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIVER ANTIGEN; URSODEOXYCHOLIC ACID; IMMUNOSUPPRESSIVE AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTIPHOSPHOLIPID SYNDROME; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; AUTOIMMUNE LIVER DISEASE; CONNECTIVE TISSUE DISEASE; CORTICOSTEROID THERAPY; DISEASE COURSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ESOPHAGUS VARICES; FOLLOW UP; FULMINANT HEPATIC FAILURE; GENETIC RISK; GENETIC SUSCEPTIBILITY; HASHIMOTO DISEASE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MEMBRANOUS GLOMERULONEPHRITIS; MULTICENTER STUDY (TOPIC); OVERLAP SYNDROME; PORTAL HYPERTENSION; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; RISK FACTOR; SYSTEMIC SCLEROSIS; DIFFERENTIAL DIAGNOSIS; HEALTH; HEPATITIS, AUTOIMMUNE; SYNDROME;

DIAGNOSIS, DIFFERENTIAL; GLOBAL HEALTH; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PREVALENCE; SYNDROME;

EID: 84925688167     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.145316     Document Type: Review

References (111)

1. Washington MK. Autoimmune liver disease: Overlap and overlier. Mod Pathol 2007;20 Suppl 1:S15-30.
2. Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-Autoimmune hepatitis overlap syndrome: Clinical features and response to therapy. Hepatology 1998;28:296-301.
3. Lohse AW, zum Bushenfeld KH, Franz B, Kanzler S, Gerken G, Dienes HP. Characterization of overlap syndrome of Primary biliary cirrhosis and autoimmune hepatitis: Evidence for it being a hepatic form of primary biliary cirrhosis in genetically susceptible individuals. Hepatology 1999;29:1078-84.
4. Colombato LA, Alvarez F, Cote J, Huet PM. Autoimmune cholangiopathy the result of consecutive primary biliary cirrhosis and autoimmune hepatitis? Gastroenterology 1994;107:1839-43.
5. Twaddell WS, Lefkowitch J, Berk PD. Evolution from primary biliary cirrhosis to primary biliary cirrhosis/autoimmune hepatitis overlap syndrome. Semin Liver Dis 2008;28:128-34.
6. Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: A 16-year prospective study. Hepatology 2001:33:544-53.
7. Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome. Hepatology 2002;36:1393-9.
8. Beuers U, Rust C. Overlap syndromes. Semin Liver Dis 2005;25:311-20.
9. Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med 1996;125:588-98.
10. Mattiuzzo M, Botsios C, Biscaro R. Sequential manifestation of autoimmune diseases: An unusual case. Eur J Gastroenterol Hepatol 2006;18:777-80.
11. Patel N, Amrapurkar D, Amrapurkar A. Primary biliary cirrhosis and autoimmune hepatitis switch over: Report of two cases. Trop Gastroenterol 2005;26:136-8.
12. Beuers U. Hepatic overlap syndromes. J Hepatol 2005;42:S93-99.
13. Nezu S, Tanaka A, Yasui H, Imamura M, Nakajima H, Ishida H, et al. Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis. J Gastroenterol Hepatol 2006;21:1448-54.
14. O'Brien C, Joshi S, Feld JJ, Guindi M, Dienes HP, Heathcote EJ. Long-term follow-up of antimitochondrial antibody positive autoimmune hepatitis. Hepatology 2008;48:550-6.
15. Sato Y, Harada K, Sudo Y, Watanabe K, Nakahama T, Morimoto H, et al. Autoimmune hepatitis associated with bile duct injury resembling chronic non suppurative destructive cholangitis. Pathol Int 2002;52:478-82.
16. Mishima S, Omagari K, Ohba K, Kadokawa Y, Masuda J, Mishima R, et al. Clinical implications of antimitochondrial antibodies in type I autoimmune hepatitis: A longitudinal study. Hepatogastroenterology 2008;55:221-7.
17. Poupon R. Autoimmune overlapping syndromes. Clin Liver Dis 2003;7:865-78.
18. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000;31:1231-8.
19. Ben-Ari Z, Czaja AJ. Autoimmune hepatitis and its variant syndromes. Gut 2001;49:589-94.
20. Guebel AP, Baggenstoss AH, Summerskill WH. Response to treatment can differentiate chronic active liver disease with cholangitic features from primary biliary cirrhosis. Gastroenterology 1976;71:444-49.
21. Muratori L, Cassini F, Pappas G, Guidi M, Mele L, Lorenza V, et al. The hepatic/cholestatic "overlap" syndrome: An Italian experience. Autoimmunity 2002;35:565-8.
22. Gheorghe L, Iacob S, Gheorghe C, Iacob R, Siminov I, Vadan R, et al. Frequency and predictive factors for overlap syndrome between autoimmune hepatitis and primary cholestatic liver disease. Eur J Gastroenterol Hepatol 2004;16:585-92.
23. Heurgue A, Vitry F, Diebold MD, Yaziji N, Bernard-Chabert B, Pennaforte JL, et al. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: A retrospective study of 115 cases of autoimmune liver disease. Gastroenterol Clin Biol 2007;31:17-25.
24. Gunsar F, Akarca US, Ersoz G, Karasu Z, Yuce G, Batur Y. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Hepatogastroenterology 2002;49:1195-200.
25. Talwalkar JA, Keach JC, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: An evaluation of modified scoring system. Am J Gastroenterol 2002;97:1191-7.
26. Silveira MG, Talwalkar JA, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: Long term outcomes. Am J Gastroenterol 2007;102:1244-50.
27. Joshi S, Cauch-Dudek K, Wanless IR, Lindor KD, Jorgensen R, Batts K, et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: Response to therapy with ursodeoxycholic acid. Hepatology 2002;35:409-13.
28. Suzuki Y, Arase Y, Ikeda K, Saitoh S, Tsubota A, Suzuki F, et al. Clinical and pathological characteristics of autoimmune hepatitis and primary biliary cirrhosis overlap syndrome. J Gastroenterol Hepatol 2004;19:699-706.
29. Wagle SD, Jagtap SP, Wadia F. Primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Indian J Gastroenterol 2004;23:70-1.
30. Wu CH, Wang QH, Tian GS, Xu XY, Yu YY, Wang GQ. Clinical features of the overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis: Retrospective study. Chin Med J (Engl) 2006;119:238-41.
31. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
32. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver diseases. Hepatology 1998;28:360-5.
33. Boberg KM, Fausa O, Haaland T, Holter E, Mellbye OJ, Spurkland A, et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: An evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996;23:1369-76.
34. van Buuren HR, van Hoogstraten HJ, Terkivatan T, Schalm SW, Vleggaar FP. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 2000;33:543-8.
35. Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: An evaluation of a modified scoring system. J Hepatol 2000;33;537-42.
36. Wilschanski M, Chait P, Wade JA, Davis L, Corey M, St Louis P, et al. Primary sclerosing cholangitis in 32 children: Clinical, laboratory and radiographic features with survival analysis. Hepatology 1995;22:1415-22.
37. Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid treated autoimmune hepatitis. J Hepatol 1992;14:325-31.
38. Abdalian R, Dhar P, Jhaveri K, Haider M, Guindi M, Heathcote EJ. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: Evaluating the role of routine magnetic resonance imaging. Hepatology 2008;47:949-57.
39. Rubel LR, Seeff LB, Patel V. Primary biliary cirrhosis-primary sclerosing cholangitis overlap syndrome. Arch Pathol Lab Med 1984;108:360-1.
40. Burak KW, Urbanski SJ, Swain MG. A case of coexisting Primary biliary cirrhosis and primary sclerosing cholangitis: A new overlap of autoimmune liver diseases. Dig Dis Sci 2001;46:2043-47.
41. Jeevgan A. Overlap of Primary biliary cirrhosis and primary sclerosing cholangitis-a rare coincidence or a new syndrome. Int J Gen Med 2010;3:143-6.
42. Li CP, Tong MJ, Hwang SJ, Luo JC, Co RL, Tsay SH, et al. Autoimmune cholangitis with features of autoimmune hepatitis: Successful treatment with immunosuppressive agents and ursodeoxycholic acid. J Gastroenterol Hepatol 2000;15:95-8.
43. Yamamoto K, Terada R, Okamoto R, Hiasa Y, Abe M, Onji M, et al. A scoring system for primary biliary cirrhosis and its application for variant forms of autoimmune liver disease. J Gastroenterol 2003;38:52-9.
44. Zepeda-Gomez S, Montano Loza A, Zapata Colindres JC, Paz F, Olivera-Martinez M, Lopez-Reyes A, et al. HLA-DR allele frequencies in Mexican Mestizos with autoimmune liver diseases including overlap syndromes. Immunol Invest 2009;38:276-83.
45. Honda M, Kawai H, Shirota Y, Yamashita T, Takamura T, Kaneko S. cDNA microarray analysis of autoimmune hepatitis, primary biliary cirrhosis and consecutive disease manifestation. J Autoimmun 2005;25:133-40.
46. Coss Adame E, Granados J, Uribe M, Torre A. Does HLA-DR7 differentiate the overlap syndrome of autoimmune hepatitis-primary biliary cirrhosis (AIH-PBC) from those with autoimmune hepatitis type 1?. Ann Hepatol 2011;10:28-32.
47. Weyman RL, Voigt M. Consecutive occurrence of primary biliary cirrhosis and autoimmune hepatitis: A case report and review of literature. Am J Gastroenterol 2001;96:585-7.
48. Lindgren S, Glaumann H, Almer S, Bergquist A, Bjornsson E, Broome U, et al. Transition between variant forms of primary biliary cirrhosis during long term follow-up. Eur J Intern Med 2009;20:398-402.
49. Gossard AA, Lindor KD. Development of autoimmune hepatitis in primary biliary cirrhosis. Liver Int 2007;27:1086-90.
50. Horsmans Y, Piret A, Brenard R, Rahier J, Geubel AP. Autoimmune chronic active hepatitis responsive to immunosuppressive therapy evolving into a typical primary biliary cirrhosis syndrome: A case report. J Hepatol 1994;21:194-8.
51. Van Leeuwen DJ, Sood G, Ferrante D, Lazenby AJ, Sellers MJ. A 38-year-old African American woman with an unusually rapid progression of "Primary Biliary Cirrhosis": A missed opportunity! Semin Liver Dis 2002;22:395-406.
52. Angulo P, El-Amin O, Carpenter HA, Lindor KD. Development of autoimmune hepatitis in the setting of long standing primary biliary cirrhosis. Am J Gastroenterol 2001;96:3021-7.
53. Jones DE, James OF, Portmann B, Burt AD, Williams R, Hudson M. Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Hepatology 1999;30:53-7.
54. Rodriguez-Diaz Y, Reyes-Rodriguez R, Dorta-Francisco MC, Aguilera I, Perera-Molinero A, Moneva-Arce E, et al. De novo autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Transplant Proc 2006;38:1467-70.
55. Yoshizawa K, Shirakawa H, Ichijo T, Umemura T, Tanaka E, Kiyosawa K, et al. De novo autoimmune hepatitis following living-donor liver transplantation for primary biliary cirrhosis. Clin Transplant 2008;22:385-90.
56. Hytiroglou P, Gutierrez JA, Freni M, Odin JA, Stanca CM, Merati S, et al. Recurrence of primary biliary cirrhosis and development of autoimmune hepatitis after liver transplant: A blind histologic study. Hepatol Res 2009;39:577-84.
57. Saxena R, Kim Schluger L, Klion F, Scheiner P, Thung S, Bodenheimer Jr HC. Autoimmune hepatitis in the liver allografts of patients transplanted for PBC and overlap syndrome. Gastroenterology 1998;114:A1335.
58. Kayacetin E, Koklu S, Temucin T. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis with unusual initial presentation as fulminant hepatic failure. Dig Liver Dis 2004;36:419-22.
59. Lee H, Stapp RT, Ormsby AH, Shah W. The Usefulness of IgG and IgM Immunostaining of Periportal Inflammatory Cells (Plasma Cells and Lymphocytes) for the Distinction of Autoimmune Hepatitis and Primary Biliary Cirrhosis and Their Staining Pattern in Autoimmune Hepatitis-Primary Biliary Cirrhosis Overlap Syndrome. Am J Clin Pathol 2010;133:430-7.
60. Invernizzi P, Podda M, Battezzati PM, Crosignani A, Zuin M, Hitchman E, et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 2001;34:366-72.
61. Muratori P, Muratori L, Ferrari R, Cassani F, Bianchi G, Lenzi M, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003;98:431-7.
62. Muratori P, Granito A, Pappas G, Pendino GM, Quarneti C, Cicola R, et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol 2009;104:1420-5.
63. Kanzler S, Bozkurt S, Herkel J, Galle PR, Dienes HP, Lohse AW. Presence of SLA/LP autoantibodies in patients with primary biliary cirrhosis as a marker for secondary autoimmune hepatitis (overlap syndrome). Dtsch Med Wochenschr 2001;126:450-6.
64. Czaja AJ, Shums Z, Norman GL. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity 2002;35;475-83.
65. Csepregi A, Obermayer-Straub P, Kneip S, Kayser A, Loges S, Schmidt E, et al. Characterization of a lipoyl domain-independent B-cell autoepitope on the human branched chain acyltransferase in primary biliary cirrhosis and overlap syndrome with autoimmune hepatitis. Clin Dev Immunol 2003;10:173-81.
66. Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E; International Autoimmune Hepatitis Group. Overlap Syndromes: The International Autoimmune Hepatitis Group (IAIHG) Position Statement on a Controversial Issue. J Hepatol 2011;54:374-85.
67. Kuiper EM, Zondervan PE, van Buure HR. Chazouilleres criteria are superior to the revised and simplified autoimmune hepatitis scores for diagnosing the overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis. J Hepatol 2009;50:S246-7.
68. Kuiper EM, Zondervan PE, van Buure HR. Paris Criteria Are Effective in Diagnosis of Primary Biliary Cirrhosis and Autoimmune Hepatitis Overlap Syndrome. Clin Gastroenterol Hepatol 2010;8:530-4.
69. Toyoda M, Yokomori H, Kaneko F, Yoshida H, Hoshi K, Takeuchi H, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome concomitant with systemic sclerosis, immune thrombocytopenic purpura. Intern Med 2009;48:2019-23.
70. Targoñska-Stepniak B, Majdan M, Suszek D, Laskowska K. Overlap syndrome autoimmune hepatitis and primary biliary cirrhosis associated with antiphospholipid syndrome. Pol Merkur Lekarski 2006;21:480-3.
71. Arakawa Y, Amaki S, Miyakawa H, Sakai T, Gotou I, Tanaka N, et al. PBC-AIH overlap syndrome with concomitant ITP and Hashimoto's disease with positivity for anti-centromere antibody. J Gastroenterol 2004;39:490-5.
72. Gentile M, Verta M, Vigna E, Lucia E, Mazzone C, Perugini D, et al. Autoimmune hemolityc anemia concomitant with sequential autoimmune hepatitis-primary biliary cirrhosis overlap syndrome and Hashimoto's thyroiditis: A new entity of autoimmune polyendocrine syndrome. J Endocrinol Invest 2009;32:287-8.
73. Efe C, Ozaslan E, Purnak T, Ozturk R. Membranous glomerulonephritis associated with autoimmune hepatitis and primary biliary cirrhosis overlap syndrome: A very rare condition. Eur J Gastroenterol Hepatol 2010;22:1149-50.
74. Czaja AJ. Treatment of autoimmune hepatitis. Semin Liver Dis 2002;22:365-78.
75. Levy C, Lindor KD. Management of osteoporosis, fat soluble vitamin deficiencies and hyperlipidemia in primary biliary cirrhosis. Clin Liver Dis 2003;7:901-10.
76. Chazouilleres O, Wendum D, Serfaty L, Rosmorduc O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2006;44:400-6.
77. Duclos-Vallee JC, Hadengue A, Ganne-Carrie N, Robin E, Degott C, Erlinger S. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Corticoresistance and effective treatment by Cyclosporine A. Dig Dis Sci 1995;40:1069-73.
78. Alric L, Thebault S, Selves J, Peron JM, Mejdoubi S, Fortenfant F, et al. Characterization of overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis according to antimitochondrial antibodies status Gastroentérol Clin Biol 2007;31:11-6.
79. Czaja AJ, Santrach PJ, Breanndan Moore S. Shared genetic risk factors in autoimmune liver disease. Dig Dis Sci 2001;46:140-7.
80. Chapman RW, Varghese Z, Gaul R, Patel G, Kokinon N, Sherlock S. Association of primary sclerosing cholangitis with HLA-B8. Gut 1983;24:38-41.
81. Prochazka EJ, Terasaki PI, Park MS, Goldstein LI, Busuttil RW. Association of primary sclerosing cholangitis with HLA-DRw52a. N Engl J Med 1990;322:1842-4.
82. Donaldson PT, Farrant JM, Wilkinson ML, Hayllar K, Portmann BC, Williams R. Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology 1991;13:129-33.
83. Farrant JM, Doherty DG, Donaldson PT, Vaughan RW, Hayllar KM, Welsh KI, et al. Amino acid substitutions at position 38 of the DRâ polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology 1992;16:390-5.
84. Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002;359:150-7.
85. Agace WW. T-cell recruitment to the intestinal mucosa. Trends Immunol 2008;29:514-22.
86. Eksteen B, Grant AJ, Miles A, Curbishley SM, Lalor PF, Hubscher SG, et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9? gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med 2004;200:1511-7.
87. Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M, et al. Autoimmune hepatitis in childhood: A 20 year survey. Hepatology 1997;25:541-7.
88. Mieli-Vergani G, Vergani D. Immunological liver diseases in children. Semin Liver Dis 1998;18:271-9.
89. Roberts EA. Primary sclerosing cholangitis in children. J Gastroenterol Hepatol 1999;14:588-93.
90. Mieli-Vergani G. Autoimmune sclerosing cholangitis: A distinct clinical entity? J Hepatol 2000;32:7-8.
91. Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992;14:325-31.
92. Wee A, Ludwig J. Pericholangitis in chronic ulcerative colitis: Primary sclerosing cholangitis of the small bile ducts? Ann Intern Med 1985;102:581-7.
93. McNair AN, Moloney M, Portmann BC, Williams R, McFarlane IG. Autoimmune hepatitis overlapping primary sclerosing cholangitis in five cases. Am J Gastroenterol 1998;93:777-84.
94. Goldstein NS, Soman A, Gordon SC. Portal tract eosinophils and hepatocyte cytokeratin 7 immunoreactivity helps distinguish early stage, mildly active primary biliary cirrhosis and automimune hepatitis. Am J Clin Pathol 2001;116:846-53.
95. Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol 2008;14:331-7.
96. Malik TA, Gutierrez AM, McGuire B, Zarzour JG, Mukhtar F, Bloomer J. Autoimmune Hepatitis-Primary Sclerosing Cholangitis Overlap Syndrome Complicated by Crohn's Disease. Digestion 2010;82:24-6.
97. Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: An evaluation of a modified scoring system. J Hepatol 2000;33:537-42.
98. Chazouilleres O. Diagnosis of primary sclerosing cholangitis-autoimmune hepatitis overlap syndrome: To score or not to score? J Hepatol 2000;33:661-3.
99. Saltik-Temizel NI, Koçak N, Ergen FB, Akhan O. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome with inflammatory bowel disease in a boy: Role of MR cholangiopancreatography in the diagnosis. Eur J Radiol 2004;50:45-7.
100. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high dose ursodeoxycholic acid as a therapy in primary sclerosing cholangitis. Gastroenterology 2001;121:900-7.
101. Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD. High dose ursodeoxycholic acid as atherapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001;96:1558-62.
102. Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo-controlled trial. Hepatology 1992;16:707-14.
103. Lindor KD. Ursodiol for primary sclerosing cholangitis Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997;336:691-5.
104. Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis: A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994;20:57-64.
105. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808-14.
106. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89-95.
107. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889-93.
108. Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011;106:1638-45.
109. Lindstrom L, Boberg KM, Wikman O, Friis-Liby I, Hultcrantz R, Prytz H, et al. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther 2012;35:451-7.
110. Oo YH, Hubscher SG, Adams DH. Autoimmune hepatitis: New paradigms in the pathogenesis, diagnosis, and management. Hepatol Int 2010;4:475-93.
111. Al-Chalabi T, Portmann BC, Bernal W, Mcfarlene IG, Heneghan MA. Autoimmune hepatitis overlap syndromes: An evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther 2008;28:209-20.